Patent intelligence · US
US 11903993
Ready-to-use bivalirudin compositions
Ready-to-use bivalirudin compositions
Patent details — US 11903993
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 20, 2024
- Expiration
- Feb 15, 2044
- Applicant
- MAIA PHARMACEUTICALS, INC.
- Claims
- 6
- CPC classes
- A61K, A61K38/10, A61K38/58, A61K47/02
Quick answer
US 11903993 (Ready-to-use bivalirudin compositions) is held by MAIA PHARMACEUTICALS, INC.. Status: granted. Granted Feb 20, 2024. Expires Feb 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MAIA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K38/10, A61K38/58, A61K47/02, A61K47/10, A61K47/12
More from MAIA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12005069
Bortezomib compositions
granted -
US 11992514
Ready-to-use bivalirudin compositions
granted -
US 11918622
Ready-to-use bivalirudin compositions
granted -
US 11752164
Bortezomib compositions
granted -
US 11737983
Storage stable sincalide formulations
granted -
US 11679119
Bortezomib compositions
granted -
US 11672813
Bortezomib compositions
granted
Frequently asked questions
What is US patent 11903993?
US 11903993 (Ready-to-use bivalirudin compositions) is held by MAIA PHARMACEUTICALS, INC.. Status: granted. Granted Feb 20, 2024. Expires Feb 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11903993?
MAIA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 11903993 expire?
Our index shows an expiration date of Feb 15, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.